TLR9 and glioblastoma: To date, TLR9-targeted therapy options in GBM potentially cover the administration of CpG-28, CpG-ODN-1668, CpG-ODN-107, CpG-1826, CpG-1826 and CpG-ODN without or with various chemotherapeutic agents [123].